A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
Public ClinicalTrials.gov record NCT00362466. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Randomized Phase III Study of Dasatinib vs. High-Dose (600 mg) Imatinib Mesylate in the Treatment of Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Are Imatinib Failures or Who Have Had a Suboptimal Response After 3-18 Months of Therapy With 400 mg Imatinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical research study is to compare the rate of complete cytogenetic response of dasatinib to imatinib therapy at 6 months after randomization in chronic phase CML patients. The safety of this treatment will also be studied.
Study identification
- NCT ID
- NCT00362466
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 3 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2007 (Type not available)
- Primary completion
- Jun 2008 (Actual)
- Completion
- Jun 2008 (Actual)
- Last update posted
- Nov 20, 2009
2007 – 2008
United States locations
- U.S. sites
- 45
- U.S. states
- 22
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dr. Marshall Schreeder | Huntsville | Alabama | 35805 | — |
| Local Institution | Little Rock | Arkansas | 72205 | — |
| Local Institution | Alhambra | California | 91801 | — |
| Local Institution | Anaheim | California | 92801 | — |
| Local Institution | Beverly Hills | California | 90211 | — |
| Local Institution | Fullerton | California | 92835 | — |
| Local Institution | La Jolla | California | 92093 | — |
| Local Institution | La Verne | California | 91750 | — |
| Local Institution | Long Beach | California | 90813 | — |
| Local Institution | Los Angeles | California | 90033 | — |
| Local Institution | Los Angeles | California | 90048 | — |
| Local Institution | Los Angeles | California | 90095 | — |
| Local Institution | Northridge | California | 91325 | — |
| Local Institution | Oxnard | California | 93030 | — |
| Local Institution | Redondo Beach | California | 90277 | — |
| Local Institution | San Francisco | California | 94143 | — |
| Local Institution | Santa Maria | California | 93454 | — |
| Local Institution | Stanford | California | 94305 | — |
| Local Institution | Aurora | Colorado | 80045 | — |
| Local Institution | Jacksonville | Florida | 32207 | — |
| Local Institution | Jacksonville | Florida | 32209 | — |
| M.D. Anderson Cancer Center Orlando | Orlando | Florida | 32806 | — |
| Local Institution | Pembroke Pines | Florida | 33028 | — |
| Local Institution | Chicago | Illinois | 60637 | — |
| Local Institution | Indianapolis | Indiana | 46202 | — |
| Local Institution | Kansas City | Kansas | 66160 | — |
| Local Institution | Hazard | Kentucky | 41701 | — |
| Local Institution | Ann Arbor | Michigan | 48109 | — |
| Local Institution | Rochester | Minnesota | 55905 | — |
| Local Institution | St Louis | Missouri | 63110 | — |
| Local Institution | Omaha | Nebraska | 68114 | — |
| Local Institution | Las Vegas | Nevada | 89135 | — |
| Local Institution | Hackensack | New Jersey | 07601 | — |
| Local Institution | Buffalo | New York | 14263 | — |
| New York Presbyterian Hospital | New York | New York | 10021 | — |
| New York Medical College | Valhalla | New York | 10595 | — |
| Local Institution | Durham | North Carolina | 27710 | — |
| Local Institution | Cleveland | Ohio | 44195 | — |
| Local Institution | Oklahoma City | Oklahoma | 73112 | — |
| Local Institution | Tulsa | Oklahoma | 74136 | — |
| Local Institution | Baltimore | Pennsylvania | 21229 | — |
| Local Institution | Pittsburgh | Pennsylvania | 15232 | — |
| Santee Hematology/Oncology | Sumter | South Carolina | 29150 | — |
| Local Institution | Dallas | Texas | 75390 | — |
| Local Institution | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00362466, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2009 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00362466 live on ClinicalTrials.gov.